16154-62-4

Basic information

• Product Name: BUTTPARK 83\09-70
• Synonyms: BUTTPARK 83\09-70;1-(2-CHLORO-4-NITROPHENYL)-4-METHYLPIPERAZINE;1-(2-Chloro-4-nitrophenyl)
• CAS NO: 16154-62-4
• Molecular Formula: C₁₁H₁₄ClN₃O₂
• Molecular Weight: 255.7
• EINECS: 200-589-5
• Mol File: 16154-62-4.mol
• Article Data: 10

Chemical Properties

• Melting Point: 106 °C
• Boiling Point: 384.87 °C at 760 mmHg
• Flash Point: 186.563 °C
• Appearance: /Solid
• Density: 1.301 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 7.18±0.42(Predicted)
• CAS DataBase Reference: BUTTPARK 83\09-70(CAS DataBase Reference)
• NIST Chemistry Reference: BUTTPARK 83\09-70(16154-62-4)
• EPA Substance Registry System: BUTTPARK 83\09-70(16154-62-4)

Safety Data

• Hazardous Substances Data: 16154-62-4(Hazardous Substances Data)

Usage

General Description

"BUTTPARK 83\09-70" appears to be an incorrect term as it is not associated with any known chemical or substance in scientific databases or industrial catalogs. It's possible that this may be a typographical error or a proprietary name related to a specific industry application. Please provide more details or the correct chemical name for a more accurate response.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 350-30-1 3-chloro-4-fluoronitrobenzene 
• 99-54-7 3,4-dichloronitrobenzene 

Downstream Products

• 16154-72-6 3-chloro-4-(4-methylpiperazin-1-yl)benzenamine 

Relevant articles and documents

PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER

The invention provides compounds of the formula (1): or a salt or tautomer thereof wherein A, R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are inhibitors of Wee1 and/or PLK1 kinase and are envisaged to be useful in the treatment of cancers.

WEE1 inhibitors as well as preparation and application thereof

The invention relates to WEE1 inhibitors as well as preparation and application thereof. The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, solvates, polymorphs or isomers thereof, and their use in the preparation of medicaments for the treatment of diseases associated with WEE1 activity.

POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS

Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.